BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
The start-up claims in clinical trials over 90 % achieved type 2 diabetes reversal and 92 % eliminated all diabetes medication within 90 days of joining the twin service
The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
Barbara Engelhardt moves her computational and statistics lab to Gladstone
Packaged junk food which is a major component of unhealthy diets is responsible for more deaths worldwide than any other risk factor
New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis. Heart failure accounts for more than one million hospitalisations a year in the US
FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.
It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
The company is eligible for 12 months exclusivity from launch
Subscribe To Our Newsletter & Stay Updated
